Cancer is a complex disease that can evade the immune system's natural defenses. However, recent advancements in immunotherapy have revolutionized cancer treatment by using the body's own immune system to fight cancer. Monoclonal antibodies (mAbs) and immune checkpoint inhibitors are two types of immunotherapy that have shown promise in treating various types of cancer.
Monoclonal antibodies are laboratory-produced antibodies that are designed to recognize and target specific proteins on the surface of cancer cells. These antibodies can be used alone or in combination with other therapies such as chemotherapy or radiation. Monoclonal antibodies work by binding to cancer cells and blocking their ability to grow and divide, or by marking them for destruction by the immune system. For example, trastuzumab (Herceptin) is a monoclonal antibody that targets HER2-positive breast cancer cells and can be used in combination with chemotherapy to improve survival rates.
Immune checkpoint inhibitors, on the other hand, are a type of immunotherapy that work by blocking proteins on cancer cells or immune cells, allowing the immune system to better attack the cancer. They work by blocking the checkpoint proteins on T cells that prevent them from attacking cancer cells. When these checkpoint proteins are blocked, T cells are activated and can recognize and destroy cancer cells. ICIs have shown promising results in the treatment of several types of cancer, including melanoma, lung cancer, and bladder cancer. They are typically administered through intravenous infusion
ICIs are often used in combination with other cancer therapies, such as chemotherapy or radiation therapy, to improve treatment outcomes. While ICIs have revolutionized cancer therapy, they are not effective for all patients and further research is needed to identify biomarkers that can predict which patients will benefit from this treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Cancer is a complex disease that can evade the immune system's natural defenses. However, recent advancements in immunotherapy have revolutionized cancer treatment by using the body's own immune system to fight cancer. Monoclonal antibodies (mAbs) and immune checkpoint inhibitors are two types of immunotherapy that have shown promise in treating various types of cancer.
Monoclonal antibodies are laboratory-produced antibodies that are designed to recognize and target specific proteins on the surface of cancer cells. These antibodies can be used alone or in combination with other therapies such as chemotherapy or radiation. Monoclonal antibodies work by binding to cancer cells and blocking their ability to grow and divide, or by marking them for destruction by the immune system. For example, trastuzumab (Herceptin) is a monoclonal antibody that targets HER2-positive breast cancer cells and can be used in combination with chemotherapy to improve survival rates.
Immune checkpoint inhibitors, on the other hand, are a type of immunotherapy that work by blocking proteins on cancer cells or immune cells, allowing the immune system to better attack the cancer. They work by blocking the checkpoint proteins on T cells that prevent them from attacking cancer cells. When these checkpoint proteins are blocked, T cells are activated and can recognize and destroy cancer cells. ICIs have shown promising results in the treatment of several types of cancer, including melanoma, lung cancer, and bladder cancer. They are typically administered through intravenous infusion
ICIs are often used in combination with other cancer therapies, such as chemotherapy or radiation therapy, to improve treatment outcomes. While ICIs have revolutionized cancer therapy, they are not effective for all patients and further research is needed to identify biomarkers that can predict which patients will benefit from this treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.